Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Rebecca L. Skalsky has a total of 89 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Human cytomegalovirus microRNAs target the Wnt signaling protein Dishevelled 3 to promote efficient reactivation in CD34 + hematopoietic progenitor cells

    by Nicole L Diggins, Luke Slind, Jennifer Mitchell, Andrew H Pham, Devin N Fachko, Yan Chen, Rebekah L Turner, Patrizia Caposio, Rebecca L Skalsky, Meaghan H Hancock

    Human cytomegalovirus (HCMV) establishes latency in CD34 + hematopoietic progenitor cells (HPCs), yet differentiation of these cells promotes viral gene expression and replication. HCMV must therefore precisely regulate the signaling networks that govern HPC fate to maintain latency while preserving the capacity for reactivation. Virally encoded microRNAs (miRNAs) represent powerful tools used by HCMV to manipulate cellular pathways that are involved in HPC fate decisions. Wnt (Wingless/Integrated)/β-catenin signaling represents one such pathway that plays a critical role in regulating both hematopoiesis and virus replication. Previous work determined that HCMV stimulates β-catenin activity during reactivation in CD34 + HPCs. In contrast, here we show that HCMV miRNAs miR-US5-2 and miR-US25-2 downregulate the Wnt pathway adaptor protein Dvl3 during latency and that this downregulation is required for subsequent virus reactivation. These findings support a model of temporally distinct regulation of Wnt pathway components during latency and reactivation. IMPORTANCE: Human cytomegalovirus (HCMV) persists for life by establishing latency in hematopoietic progenitor cells followed by periodic reactivation events. How the virus controls host signaling pathways to influence these events remains incompletely understood. Here, we show that HCMV-encoded microRNAs (miRNAs) downregulate the Wnt signaling adaptor Dvl3 during latency, contrasting with the activation of the Wnt/β-catenin signaling that occurs during reactivation. These findings reveal that HCMV does not uniformly activate or inhibit Wnt signaling but instead regulates this pathway in opposing directions at different stages of infection. This temporal regulation of Wnt signaling highlights how HCMV coordinates viral infection with changes in progenitor cell state and identifies viral miRNAs as important regulators of the balance between latency and reactivation.

  • MicroRNA expression and functions in viral infections

    by Rebecca L. Skalsky

    MicroRNAs (miRNAs) are small, noncoding RNAs that have emerged as powerful players in the post-transcriptional regulation of gene expression. In the context of viral infections, cellular miRNAs play significant roles in modulating the complex host responses to pathogens and have essential roles in shaping viral replication. Moreover, several virus families encode viral miRNAs that manipulate the host environment and can tap into miRNA-regulated gene networks. Viral antigen expression itself can be directly miRNA regulated, and infection outcomes are substantially shaped by the miRNA activities that influence host anti-viral defense mechanisms. This review discusses common themes for both human and viral miRNAs in viral infection processes, highlighting their dual functions in both suppressing and promoting viral life cycles.

  • Open Access

    A newly developed eGFP-traceable recombinant rhesus lymphocryptovirus, a tool to study viral infection and replication in vitro and ex vivo , confirms gp350 as key for viral entry

    by Erasmus N. Kotey, Preeti Sharma, Esther Rodriguez, Jean Patrick Gonzalez-Dahua, Brenda A. Tello, Ivana G. Reidel, Gabriela M. Escalante, Yuqi Zhao, Xiwei Wu, Rodney P. Kincaid, et al.

    Epstein-Barr virus (EBV) is implicated in multiple epithelial and lymphoid malignancies worldwide; however, no licensed prophylactic vaccine exists, partly due to the lack of an adequate preclinical animal model to test candidate vaccines. Rhesus lymphocryptovirus (rhLCV) faithfully recapitulates EBV infection, persistence, and pathogenesis in rhesus macaques, offering an invaluable surrogate model. While recombinant EBV expressing enhanced green fluorescent protein (eGFP) enables swift identification of infected cells in vitro and ex vivo , an analogous tool for rhLCV has been lacking. Here, employing en passant recombination technology, we engineered a recombinant rhLCV expressing eGFP (rhLCV.eGFP) from an rhLCV bacterial artificial chromosome derived from the B-lymphoblastoid rhesus macaque cell line LCL 8664. Whole-genome sequencing confirmed sequence integrity, and functional assays demonstrated infectivity in peripheral blood mononuclear cells (PBMCs) from multiple primate species and EBV-susceptible human cell lines, and transformation competence in rhesus macaque PBMCs. To define the role of gp350/220 (gp350) in viral entry, we generated a glycoprotein gp350-deficient mutant (rhLCV.eGFPΔgp350), verified by Sanger sequencing and immunoblotting with a novel anti-gp350 monoclonal antibody (4A6). This mutant exhibited markedly reduced infectivity in rhLCV.eGFP-susceptible human B and epithelial cell lines, underscoring gp350 as a key determinant of B cell tropism, analogous to EBV gp350. Our successful engineering of rhLCV.eGFP provides a powerful platform for visualizing infection, dissecting viral entry mechanisms and cellular tropism, and advancing rhLCV as a surrogate EBV model for vaccine design, defining correlates of protection, studies of latency and reactivation, and preclinical testing of candidate antivirals and immunotherapies. IMPORTANCE: Epstein-Barr virus (EBV) infection is associated with various epithelial and lymphoid diseases. The absence of a suitable animal study model for EBV infection has hindered mechanistic studies of pathogenesis and preclinical testing of vaccines and EBV‑targeted therapies. Rhesus lymphocryptovirus (rhLCV), an EBV homolog, accurately recapitulates EBV infection and pathogenesis in rhesus macaques, offering a promising EBV surrogate model. In this study, we engineered a stable recombinant rhLCV expressing enhanced green fluorescent protein (eGFP), rhLCV.eGFP, for easy identification of infected or transformed cells in vitro and ex vivo . Further illustrating the utility of this platform, we also generated a gp350-deficient mutant rhLCV.eGFP and demonstrated markedly reduced infectivity in otherwise susceptible B and epithelial cells, confirming the EBV gp350-homologous role of rhLCV gp350 in viral entry. Thus, rhLCV.eGFP will serve as an invaluable resource for studying EBV biology and advancing the development of EBV prophylactic and therapeutic strategies using the rhLCV surrogate model.

  • Open Access

    Inhibition of type I interferon signaling is a conserved function of gamma-herpesvirus-encoded microRNAs

    by Devin N. Fachko, Yan Chen, Nikita S. Ivanov, Bonnie Goff, Brian Pendergrass, Darby G. Oldenburg, Ryan D. Estep, Scott W. Wong, Rebecca L. Skalsky

    Herpesviruses encode multiple factors that disarm innate immune signaling to evade host anti-viral responses. Several viral microRNAs expressed by Epstein-Barr virus (EBV) and Kaposi’s sarcoma-associated herpesvirus (KSHV) disrupt the induction of type I interferons (IFN) and/or the subsequent signaling events activated through type I IFN receptors. Here, we aimed to determine whether non-human primate (NHP) γ-herpesviruses (rhesus lymphocryptovirus [rLCV], rhesus rhadinovirus [RRV], and Japanese macaque rhadinovirus [JMRV]), closely related to EBV and KSHV, use similar microRNA (miRNA)-mediated strategies to regulate IFN responses. Through functional screens, we identified multiple viral miRNAs that attenuated type I IFN-mediated activation of an IFN-stimulated response element reporter and diminished expression of interferon-stimulated genes (ISGs). Infection of primary cells with miRNA-deficient rLCVs resulted in augmented expression of ISGs. Abrogation of EBV BART miRNA homologs from rLCV, in particular, led to heightened sensitivity of latently infected cells to exogenous type I IFN. Through sequence analysis and reporter assays, we show that targets of these viral miRNAs include transcripts encoding the type I IFN receptors (IFNAR1, IFNAR2) and core components of JAK/STAT signaling pathways (JAK1, IRF9). Taken together, these data demonstrate that suppression of type I IFN responses is a conserved function for NHP γ-herpesvirus miRNAs and provide important mechanistic insight into how these viral miRNAs regulate type I IFN signaling pathways. IMPORTANCE: Gamma-herpesviruses establish life-long infections in their hosts. Evading anti-viral responses is a key component of long-term viral persistence. In this work, we show that small noncoding RNAs expressed by multiple non-human primate γ-herpesviruses regulate anti-viral responses by directly targeting components of the type I interferon (IFN) signaling pathway.


  • EBV Noncoding RNAs

    by Rebecca L. Skalsky

    EBV expresses multiple viral noncoding RNAs (ncRNAs) throughout infection with regulatory activities that influence critical stages of the viral life cycle, including the establishment of latent infection and reactivation from latency. Advances in RNA sequencing technologies continue to reveal novel and diverse types of ncRNAs produced by EBV. Among these are the EBV-encoded RNAs (EBERs), the BamHI A rightward transcripts (BARTs), circular RNAs (circRNAs), stable intronic (sis) RNAs, lytic-associated ncRNAs, and viral microRNAs (miRNAs). While exact functions for most EBV ncRNAs are not fully resolved, multiple studies reveal important roles for these molecules in mediating essential aspects of the viral life cycle such as modulation of viral gene expression, cell survival, and immune evasion. This chapter updates our current knowledge of the different types of ncRNAs encoded by EBV and how these molecules critically contribute to viral persistence and disease.


  • Open Access

    Sequence Analysis of microRNAs Encoded by Simian Lymphocryptoviruses

    by Yan Chen, Devin N. Fachko, Helen L. Wu, Jonah B. Sacha, Rebecca L. Skalsky

    Lymphocryptoviruses (LCVs) are ubiquitous gamma-herpesviruses that establish life-long infections in both humans and non-human primates (NHPs). In immunocompromised hosts, LCV infections are commonly associated with B cell disorders and malignancies such as lymphoma. In this study, we evaluated simian LCV-encoded small microRNAs (miRNAs) present in lymphoblastoid cell lines (LCLs) derived from a Mauritian cynomolgus macaque (Macaca fascicularis) with cyLCV-associated post-transplant lymphoproliferative disease (PTLD) as well as the viral miRNAs expressed in a baboon (Papio hamadryas) LCL that harbors CeHV12. Via sequence comparisons, we further predicted viral miRNAs encoded by LCVs that infect two additional NHP species: stump-tailed macaques (Macaca arctoides) and bonobos (Pan paniscus). Together, these species represent two arms of the primate phylogeny: Hominoids (Pan) and Old-World monkeys (Macaca, Papio). Through our analysis, we defined sequences for >95 viral miRNAs encoded by these four NHP LCVs. Our study provides the most comprehensive annotation of NHP LCV miRNAs to date, yielding a resource for developing sequence-specific reagents to detect these molecules. Importantly, we further demonstrate that cyLCV miRNAs can be detected in circulation in vivo and have biomarker potential for LCV-related PTLD.


  • Open Access

    Functional Targets for Epstein-Barr Virus BART MicroRNAs in B Cell Lymphomas

    by Devin N. Fachko, Bonnie Goff, Yan Chen, Rebecca L. Skalsky

    MicroRNAs are key post-transcriptional regulators of gene expression and their dysregulation is often linked to cancer. Epstein-Barr virus encodes 22 BamHI A Rightward Transcript (BART) miRNAs, which are expressed in nearly all EBV-associated cancers and implicated in viral pathogenesis. To investigate biological targets for BART miRNAs in B cell lymphomas, we performed a meta-analysis of publicly available Ago-CLIP datasets from EBV-positive Burkitt lymphomas (BLs), primary effusion lymphomas (PELs), AIDS-associated diffuse large B cell lymphomas (DLBCLs), and lymphoblastoid cell lines (LCLs). Our analysis focused on comparing targets of EBV BART miRNAs across the different types of transformed B cells. Using reporter assays, we then experimentally validated over 50 functional interactions between BART miRNAs and cellular protein-coding transcripts involved in activities such as B cell differentiation (PRDM1, IRF4, and MYC), cell cycle regulation (UHMK1, CDKN1A, MDM2, and NPAT), apoptosis (MCL1), signaling and intracellular trafficking (GAB1, SOS1, MAPK1, RAB11A, CAV1, and RANBP9), and tumor suppression (CCDC6). Moreover, ectopic BART miRNA expression in several EBV-negative BL cells induced transcriptional changes that may influence molecular signatures of EBV-associated BLs. Collectively, our findings reveal novel, functional interactions for BART miRNAs in lymphomas and provide insights into their roles in these B cell cancers.


  • Open Access

    MicroRNA-focused CRISPR/Cas9 screen identifies miR-142 as a key regulator of Epstein-Barr virus reactivation

    by Yan Chen, Rodney P. Kincaid, Kelley Bastin, Devin N. Fachko, Rebecca L. Skalsky

    Reactivation from latency plays a significant role in maintaining persistent lifelong Epstein-Barr virus (EBV) infection. Mechanisms governing successful activation and progression of the EBV lytic phase are not fully understood. EBV expresses multiple viral microRNAs (miRNAs) and manipulates several cellular miRNAs to support viral infection. To gain insight into the host miRNAs regulating transitions from EBV latency into the lytic stage, we conducted a CRISPR/Cas9-based screen in EBV+ Burkitt lymphoma (BL) cells using anti-Ig antibodies to crosslink the B cell receptor (BCR) and induce reactivation. Using a gRNA library against >1500 annotated human miRNAs, we identified miR-142 as a key regulator of EBV reactivation. Genetic ablation of miR-142 enhanced levels of immediate early and early lytic gene products in infected BL cells. Ago2-PAR-CLIP experiments with reactivated cells revealed miR-142 targets related to Erk/MAPK signaling, including components directly downstream of the B cell receptor (BCR). Consistent with these findings, disruption of miR-142 enhanced SOS1 levels and Mek phosphorylation in response to surface Ig cross-linking. Effects could be rescued by inhibitors of Mek (cobimetinib) or Raf (dabrafenib). Taken together, these results show that miR-142 functionally regulates SOS1/Ras/Raf/Mek/Erk signaling initiated through the BCR and consequently, restricts EBV entry into the lytic cycle.


  • Open Access

    MicroRNA-focused CRISPR/Cas9 Screen Identifies miR-142 as a Key Regulator of Epstein-Barr Virus Reactivation

    by Yan Chen, Rodney P. Kincaid, Kelley Bastin, Devin N. Fachko, Rebecca L. Skalsky

    Reactivation from latency plays a significant role in maintaining persistent lifelong Epstein-Barr virus (EBV) infection. Mechanisms governing successful activation and progression of the EBV lytic phase are not fully understood. EBV expresses multiple viral microRNAs (miRNAs) and manipulates several cellular miRNAs to support viral infection. To gain insight into the host miRNAs regulating transitions from EBV latency into the lytic stage, we conducted a CRISPR/Cas9-based screen in EBV+ Burkitt lymphoma (BL) cells using anti-Ig antibodies to crosslink the B cell receptor (BCR) and induce reactivation. Using a gRNA library against >1500 annotated human miRNAs, we identified miR-142 as a key regulator of EBV reactivation. Genetic ablation of miR-142 enhanced levels of immediate early and early lytic gene products in infected BL cells. Ago2-PAR-CLIP experiments with reactivated cells revealed miR-142 targets related to Erk/MAPK signaling, including components directly downstream of the B cell receptor (BCR). Consistent with these findings, disruption of miR-142 enhanced SOS1 levels and Mek phosphorylation in response to surface Ig cross-linking. Effects could be rescued by inhibitors of Mek (cobimetinib) or Raf (dabrafenib). Taken together, these results show that miR-142 functionally regulates SOS1/Ras/Raf/Mek/Erk signaling initiated through the BCR and consequently, restricts EBV entry into the lytic cycle.